Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Alderdice

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|June 25, 2020
Downregulation of PPARα during Experimental Left Ventricular Hypertrophy Is Critically Dependent on Nox2 NADPH Oxidase SignallingAdam P Harvey, Emma Robinson, Kevin S Edgar, et al.
Cancer Research|February 15, 2019
ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGAAlan R Gilmore, Matthew Alderdice, Kienan I Savage, et al.
Nature Communications|June 1, 2017
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classificationPhilip D Dunne, Matthew Alderdice, Paul G O'Reilly, et al.
The Journal of Pathology|February 8, 2018
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsiesMatthew Alderdice, Susan D Richman, Simon Gollins, et al.
NAR Genomics and Bioinformatics|April 30, 2021
Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancerMatthew Alderdice, Stephanie G Craig, Matthew P Humphries, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2017
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survivalMatthew Alderdice, Philip D Dunne, Aidan J Cole, et al.
Oncotarget|August 29, 2015
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utilityMuhammad A Alvi, Darragh G McArt, Paul Kelly, et al.
Oncotarget|March 24, 2018
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancerPhilip D Dunne, Helen G Coleman, Peter Bankhead, et al.
British Journal of Cancer|July 21, 2020
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxiaStephanie G Craig, Matthew P Humphries, Matthew Alderdice, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|June 25, 2020
Downregulation of PPARα during Experimental Left Ventricular Hypertrophy Is Critically Dependent on Nox2 NADPH Oxidase SignallingAdam P Harvey, Emma Robinson, Kevin S Edgar, et al.
Cancer Research|February 15, 2019
ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGAAlan R Gilmore, Matthew Alderdice, Kienan I Savage, et al.
Nature Communications|June 1, 2017
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classificationPhilip D Dunne, Matthew Alderdice, Paul G O'Reilly, et al.
The Journal of Pathology|February 8, 2018
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsiesMatthew Alderdice, Susan D Richman, Simon Gollins, et al.
NAR Genomics and Bioinformatics|April 30, 2021
Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancerMatthew Alderdice, Stephanie G Craig, Matthew P Humphries, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2017
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survivalMatthew Alderdice, Philip D Dunne, Aidan J Cole, et al.
Oncotarget|August 29, 2015
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utilityMuhammad A Alvi, Darragh G McArt, Paul Kelly, et al.
Oncotarget|March 24, 2018
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancerPhilip D Dunne, Helen G Coleman, Peter Bankhead, et al.
British Journal of Cancer|July 21, 2020
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxiaStephanie G Craig, Matthew P Humphries, Matthew Alderdice, et al.
Pageof 1